object
studi
aim
assess
efficaci
blood
system
amotosalenultraviolet
uva
light
reduc
risk
middl
east
respiratori
syndromecoronaviru
merscov
transmiss
human
platelet
concentr
background
sinc
merscov
human
case
report
countri
infect
caus
acut
respiratori
diseas
respons
death
countri
mainli
saudi
arabia
viral
genom
rna
detect
whole
blood
serum
plasma
infect
patient
rais
concern
safeti
blood
suppli
especi
endem
area
method
four
apheresi
platelet
unit
plasma
inocul
clinic
merscov
isol
spike
unit
treat
amotosalenuva
inactiv
merscov
infecti
genom
viral
titr
quantifi
plaqu
assay
quantit
realtim
revers
transcript
polymeras
chain
reaction
rtqpcr
inactiv
sampl
success
passag
thrice
vero
cell
exclud
presenc
residu
replicationcompet
viral
particl
inactiv
platelet
complet
inactiv
merscov
spike
platelet
unit
achiev
treatment
amotosalenuva
light
mean
log
reduct
passag
correspond
salwa
hindawi
inactiv
sampl
vero
show
viral
replic
even
nine
day
incub
three
passag
viral
genom
rna
titrat
inactiv
sampl
show
titr
compar
pretreat
sampl
amotosalen
uva
light
treatment
merscovspik
platelet
concentr
effici
complet
inactiv
merscov
infect
log
suggest
treatment
could
minimis
risk
transfusionrel
merscov
transmiss
treatment
acut
bleed
due
trauma
surgeri
prevent
bleed
patient
due
indic
reli
transfus
blood
compon
save
numer
live
benefit
come
risk
pathogen
transmiss
via
transfus
blood
compon
make
suppli
safe
blood
compon
key
mission
blood
transfus
servic
introduct
screen
test
blood
product
strongli
reduc
burden
known
bloodborn
pathogen
hepat
b
c
virus
hbv
hcv
human
immunodefici
viru
hiv
howev
case
hbv
hiv
transmiss
via
blood
infect
donor
detect
serolog
screen
nucleic
acid
test
nat
describ
recent
candotti
et
al
cappi
et
al
addit
known
unknown
pathogen
pose
potenti
threat
blood
safeti
region
differ
number
differ
pathogen
screen
test
appli
blood
bank
usual
limit
econom
factor
avail
reliabl
afford
assay
thu
efficaci
pathogen
inactiv
technolog
viabl
altern
serolog
nat
test
risk
transmiss
broad
spectrum
pathogen
reduc
also
reduc
need
implement
addit
screen
test
proven
effici
prows
middl
east
respiratori
syndromecoronaviru
merscov
describ
endem
zoonot
pathogen
saudi
arabia
countri
arabian
peninsula
sinc
zaki
et
al
dromedari
camel
like
anim
reservoir
viru
spread
anim
caus
human
infect
azhar
et
al
late
may
confirm
infect
includ
death
mortal
rate
report
countri
major
confirm
case
total
report
saudi
arabia
mortal
rate
http
wwwwhointemergenciesmerscoven
symptom
mer
infect
vari
asymptomat
sever
pneumonia
zaki
et
al
mackay
arden
older
age
comorbid
highest
risk
factor
develop
sever
symptom
extrapulmonari
manifest
sever
pneumonia
often
lead
fatal
outcom
almekhlafi
et
al
hospit
commun
outbreak
saudi
arabia
south
korea
report
result
nosocomi
transmiss
due
close
contact
patient
shehata
et
al
arabi
et
al
underreport
asymptomat
case
presum
thu
real
number
infect
patient
like
much
higher
number
report
confirm
case
lessler
et
al
togeth
mild
case
may
facilit
spread
viru
pose
possibl
risk
blood
safeti
higher
seroposit
camel
worker
compar
gener
popul
report
et
al
alshukairi
et
al
therefor
asymptomat
donor
may
donat
blood
potenti
carri
viru
merscov
genom
rna
detect
respiratori
serum
plasma
urin
stool
sampl
infect
patient
memish
et
al
kim
et
al
min
et
al
detect
merscov
viral
rna
plasma
serum
report
around
patient
case
associ
sever
diseas
corman
et
al
kim
et
al
min
et
al
cov
mainli
transmit
via
droplet
fomit
persontoperson
contact
direct
indirect
contact
zoonot
sourc
transfusiontransmit
merscov
infect
report
far
stramer
howev
detect
viral
rna
plasma
serum
acut
infect
patient
rais
possibl
concern
endem
area
arabian
peninsula
thu
use
pathogen
inactiv
technolog
may
crucial
prevent
transfusiontransmit
merscov
infect
outbreak
could
implement
proactiv
previs
potenti
outbreak
blood
system
technolog
inactiv
broad
spectrum
pathogen
includ
bacteria
virus
protozoa
platelet
concentr
prepar
transfus
schlenk
use
amotosalen
photoact
compound
uva
light
pathogen
genom
modifi
target
specif
manner
crosslink
genom
strand
prevent
transcript
replic
without
affect
platelet
efficaci
patient
safeti
demonstr
clinic
evalu
cid
et
al
nation
routin
observ
jutzi
et
al
haemovigil
data
multipl
countri
benjamin
et
al
addit
effect
residu
white
blood
cell
donor
inactiv
effici
gamma
irradi
castro
et
al
reduc
risk
immunolog
transfus
reaction
transfusionassoci
graftversushost
diseas
tagvhd
intercept
blood
system
current
fdaapprov
pathogen
reduct
system
platelet
although
recent
shown
intercept
treatment
effici
inactiv
merscov
human
plasma
hindawi
et
al
data
far
inactiv
merscov
intercept
treatment
platelet
extend
work
evalu
inactiv
merscov
human
apheresi
platelet
concentr
intercept
treatment
apheresi
platelet
unit
donor
plasma
ml
platelet
per
unit
collect
king
abdulaziz
univers
hospit
kauh
transfus
servic
jeddah
kingdom
saudi
arabia
voluntari
donor
use
apheresi
collect
unit
terumo
bct
japan
platelet
store
c
continu
agit
platelet
unit
screen
routin
hcvabag
hbsag
hbcab
hiv
ab
htlv
ab
syphili
well
hcv
hbv
hiv
nat
donor
also
confirm
neg
merscovneutralis
antibodi
baselin
sampl
remain
volum
ml
remain
platelet
count
four
unit
ad
platelet
use
studi
platelet
unit
inocul
merscov
stock
dilut
platelet
unit
treat
intercept
larg
volum
process
set
intercept
illumin
ceru
corpor
usa
residu
amotosalen
free
photoproduct
remov
use
integr
compound
adsorpt
devic
accord
manufactur
instruct
follow
sampl
collect
test
posit
control
sampl
viru
stock
neg
control
sampl
platelet
inocul
viru
pretreat
sampl
inocul
platelet
sampl
treat
platelet
detect
replic
merscov
intercepttr
platelet
perform
previous
describ
minor
modif
pinna
et
al
hindawi
et
al
briefli
collect
pretreat
inactiv
sampl
dilut
dilut
dmem
fb
contain
heparin
sulphat
uml
inocul
vero
cell
plate
duplic
incub
h
c
inoculum
remov
replac
ml
dmem
fb
incub
day
c
day
three
postinocul
supernat
collect
plate
dilut
dmem
fb
reinocul
vero
cell
two
success
passag
supernat
collect
passag
also
use
viral
load
quantif
quantit
realtim
revers
transcript
polymeras
chain
reaction
rtqpcr
experi
plate
maintain
nine
day
inocul
observ
cytopath
effect
cpe
ensur
absenc
residu
infecti
virus
plaqu
assay
perform
previous
describ
hindawi
et
al
minor
modif
briefli
sampl
serial
dilut
dmem
fb
contain
heparin
sulphat
uml
start
ml
dilut
inocul
confluent
vero
cell
monolay
incub
h
c
inoculum
remov
replac
overlay
media
dmem
agaros
incub
day
c
incub
cell
stain
neutral
red
h
c
plaqu
count
calcul
titr
plaqueform
unit
pfu
ml
viral
rna
extract
sampl
collect
directli
platelet
unit
posit
neg
pretreat
posttreat
sampl
well
cell
supernat
use
qiagen
viral
rna
mini
kit
qiagen
germani
accord
manufactur
instruct
rel
quantif
merscov
viral
load
perform
previous
describ
hashem
et
al
modif
brief
onestep
realtim
rtqpcr
conduct
use
merscovspecif
primer
probe
target
upstream
region
e
gene
upe
quantitect
probe
rtpcr
kit
qiagen
germani
appli
biosystem
fast
realtim
pcr
system
ct
valu
replic
sampl
analys
ct
valu
standard
curv
merscov
known
mrna
copi
number
viral
load
express
equival
log
equival
per
ml
tcid
eqml
compar
pretreat
sampl
run
includ
posit
viral
templat
control
notempl
neg
control
sampl
test
duplic
mean
report
tcid
eqml
studi
approv
biomed
ethic
committe
unit
king
abdulaziz
univers
hospit
approv
spike
four
unit
ad
human
platelet
collect
healthi
donor
merscov
spike
unit
treat
nd
detect
amotosalen
uva
light
mean
infecti
viral
titr
pretreat
sampl
four
unit
log
pfuml
rang
log
pfuml
tabl
treatment
spike
unit
result
mean
reduct
log
pfuml
infecti
viru
detect
plaqu
assay
tabl
fig
show
repres
plaqu
assay
result
test
unit
expect
test
neg
control
sampl
collect
spike
merscov
show
replicationcompet
viru
note
viral
infect
titr
posit
control
mean
log
pfuml
rang
log
pfuml
reduc
log
pfuml
rang
log
pfuml
spike
platelet
unit
lower
expect
dilut
log
previous
observ
plasma
hindawi
et
al
suggest
platelet
andor
plasma
may
impact
merscov
infect
titr
probabl
due
nonspecif
inhibit
use
sampl
neg
merscov
antibodi
confirm
result
viral
genom
titr
determin
collect
sampl
shown
tabl
posit
control
pretreat
sampl
unit
log
tcid
eqml
equival
infecti
viral
titr
determin
plaqu
assay
shown
tabl
importantli
posttreat
sampl
show
viral
genom
titr
slightli
reduc
compar
titr
pretreat
sampl
result
suggest
amotosalen
uva
light
inactiv
infecti
virus
without
signific
effect
viral
genom
titr
shown
merscov
dengu
viru
zika
viru
musso
et
al
santa
maria
et
al
hindawi
et
al
exclud
possibl
residu
replic
merscov
associ
presenc
viral
genom
titr
treat
platelet
unit
tabl
inocul
collect
sampl
vero
cell
evalu
infect
three
success
passag
although
cultur
pretreat
sampl
nd
detect
data
shown
log
tcid
eqml
titr
determin
sampl
use
tabl
show
complet
cpe
within
day
postinocul
similar
posit
control
cpe
observ
cell
inocul
inactiv
sampl
similar
neg
tabl
use
experi
sampl
use
dilut
titr
determin
day
postinocul
mock
control
fig
even
nine
day
incub
three
passag
confirm
determin
viral
genom
titr
supernat
collect
passag
inocul
either
pretreat
posttreat
sampl
shown
tabl
passag
pretreat
sampl
led
viral
replic
increas
viral
titr
upon
passag
hand
viral
infect
titr
cell
inocul
inactiv
sampl
decreas
lower
undetect
level
cultur
supernat
togeth
data
confirm
complet
inactiv
merscov
test
platelet
unit
absenc
replicationcompet
viru
postinactiv
outbreak
emerg
pathogen
pose
high
risk
blood
safeti
screen
test
often
avail
occurr
spread
impact
difficult
predict
make
hard
implement
safeti
measur
appropri
time
manner
recent
chikungunya
viru
outbreak
itali
sever
impact
blood
avail
lazio
region
caus
offici
demand
halt
platelet
suppli
centr
region
intercept
technolog
implement
allow
continu
platelet
product
prepar
could
thu
prevent
complet
stop
platelet
suppli
support
hospit
entir
region
vairo
et
al
italian
outbreak
second
ravenna
outbreak
yet
anoth
exampl
recent
emerg
arboviru
outbreak
mediterranean
like
enabl
spread
vector
due
global
warm
increas
intern
travel
good
exchang
zika
viru
outbreak
south
central
america
anoth
exampl
high
number
asymptomat
carrier
made
difficult
protect
blood
suppli
lanteri
et
al
although
best
knowledg
transmiss
merscov
blood
transfus
yet
report
detect
merscov
genom
rna
blood
infect
patient
rais
concern
blood
safeti
stramer
viral
genom
rna
detect
plasma
serum
patient
merscov
outbreak
saudi
arabia
south
korea
give
rise
concern
potenti
transmiss
blood
transfus
viral
load
log
genom
copi
per
ml
whole
blood
log
genom
copi
per
ml
serum
report
south
korea
kim
et
al
viral
load
log
genom
copi
per
ml
correspond
log
infecti
viru
serum
also
report
outbreak
saudi
arabia
corman
et
al
although
report
transfusionrel
merscov
transmiss
far
viral
rna
could
detect
patient
blood
almost
two
week
postdiagnosi
corman
et
al
may
repres
possibl
rout
transmiss
especi
sever
studi
shown
replic
sever
blood
cell
chu
et
al
zhou
et
al
furthermor
aabb
list
merscov
pathogen
concern
blood
safeti
stramer
therefor
import
investig
possibl
way
reduc
risk
transmiss
avoid
effect
blood
suppli
especi
endem
region
saudi
arabia
could
lead
deferr
donat
confirm
suspect
case
happen
sarscov
outbreak
http
wwwwhointcsr
sarsguidelinesbloodsafetyen
previous
describ
inactiv
merscov
spike
human
plasma
sampl
hindawi
et
al
averag
log
reduct
infecti
titr
amotosalenuva
treatment
studi
report
mean
log
reduct
infecti
titr
merscov
virusspik
platelet
sampl
indic
amotosalenuva
treatment
merscovspik
platelet
effect
inactiv
viru
potenti
reduc
risk
merscov
transmiss
contamin
platelet
unit
reduct
least
one
log
higher
possibl
infecti
titr
serum
report
previous
corman
et
al
note
inactiv
mechan
intercept
treatment
depend
crosslink
nucleic
acid
strand
therebi
prevent
pathogen
replic
given
size
amplicon
detect
viral
genom
rna
rtqpcr
still
possibl
inactiv
genom
titr
slightli
affect
pathogen
inactiv
treatment
find
unusu
previous
report
success
inactiv
virus
specif
amotosalenuva
light
inactiv
process
result
crosslink
pathogen
nucleic
acid
strand
sequencespecif
manner
adduct
form
nucleic
acid
thu
inhibit
transcript
replic
howev
crosslink
necessarili
site
target
rtpcr
thu
treatment
expect
affect
viral
replic
nucleic
acid
remain
detect
explain
genom
titr
reduc
similar
fashion
infect
reduct
nonetheless
addit
safeti
assess
presenc
residu
replicationcompet
particl
inactiv
platelet
unit
passag
three
success
time
three
day
show
cpe
inactiv
unit
viral
genom
also
detect
nine
day
three
passag
show
loss
replicationincompet
particl
passag
confirm
total
inactiv
viral
particl
treat
platelet
unit
one
major
limit
studi
use
four
human
platelet
unit
subsequ
studi
includ
larger
number
sampl
although
addit
amotosalen
alon
without
uva
light
reduc
viral
titr
spike
sampl
data
shown
effect
adsorpt
step
alon
without
amotosalen
uva
light
test
studi
includ
subsequ
work
determin
effect
step
inactiv
process
addit
futur
studi
also
investig
possibl
effect
amotosalen
uva
light
treatment
viral
particl
inactiv
may
also
occur
via
path
directli
associ
genom
alter
coval
crosslink
viral
protein
oxid
reaction
induc
singlet
oxygen
gener
process
furthermor
possibl
viru
attach
adher
platelet
even
internalis
platelet
test
nonetheless
data
show
whole
inactiv
process
effect
reduc
risk
viru
transmiss
via
transfus
recent
studi
report
reduct
log
merscov
spike
platelet
prepar
pa
plasma
use
uvc
light
eickmann
et
al
addit
minimum
reduct
log
merscov
plasma
report
use
methylen
blue
visibl
light
eickmann
et
al
riboflavin
uv
light
keil
et
al
respect
although
report
shown
mark
reduct
infecti
viral
titr
repres
accept
safeti
margin
accord
european
committe
blood
transfus
presenc
remain
low
level
replicationcompet
viru
treatment
investig
confirm
complet
inactiv
viru
addit
would
interest
observ
effect
inactiv
treatment
genom
viral
load
correl
result
mean
genom
titr
merscov
patient
studi
show
effici
inactiv
merscov
isol
spike
human
platelet
concentr
plasma
amotosalenuva
complet
inactiv
mean
log
reduct
viral
titr
confirm
passag
experi
exclud
remain
replicationcompet
particl
technolog
repres
effici
method
reduc
possibl
risk
associ
merscov
well
virus
may
transmit
via
blood
transfus
